We offer both intramuscular and intravenous infusions
The same compound acquired or supplied with intent that it be administered to humans for a therapeutic purpose is regulated as a therapeutic good, regardless of whether it is labelled "for research use only." This distinction is why the "research use only" labelling common on peptide supply websites does not confer legal protection when the supply model is clearly oriented toward human use
Other studies that assessed cortical GSH levels by proton magnetic resonance spectroscopy suggested that GSH may be a biomarker of depression, with lower levels in patients with major depression (Lapidus et al., 2014)
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Improving insulin sensitivity Insulin resistance can result in the development of type 2 diabetes
.png)
